Toronto General Hospital - UHN
Welcome,         Profile    Billing    Logout  
 11 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lok, Charmaine
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease

Recruiting
N/A
3600
Europe, Canada, RoW
Liberal phosphate target, Intensive phosphate target
The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago
Kidney Failure, Chronic, Hyperphosphatemia
12/27
12/28
NCT04932148: INCremental Dialysis to Improve Health Outcomes in People Starting Haemodialysis (INCH-HD)

Recruiting
N/A
372
Canada, RoW
Incremental HD, Conventional HD
The University of Queensland, Medical Research Future Fund, Queensland Health, Canadian Institutes of Health Research (CIHR)
Kidney Failure
08/26
08/26
Cherney, David
NCT04620590: An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Recruiting
4
17
Canada
Dapagliflozin 10 MG [Farxiga]
George Clinical Pty Ltd, University Medical Center Groningen, Ground Zero Pharmaceuticals
Diabetes Mellitus, Type 2, Impaired Renal Function
03/22
04/22
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SUGARNSALT, NCT06217302: Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease

Recruiting
3
150
Canada, US
Sotagliflozin, INPEFA, Placebo
Alessandro Doria, Canadian Institutes of Health Research (CIHR), The Kidney Foundation of Canada, The Cleveland Clinic, University of Michigan, University of Colorado, Denver, Northwestern University, Washington University School of Medicine, State University of New York - Upstate Medical University, Providence Medical Research Center, Stanford University, Montefiore Medical Center, University of Toronto, University Health Network, Toronto, University of Calgary, University of Alberta, University of British Columbia, Institut de Recherches Cliniques de Montreal, LMC Diabetes & Endocrinology Ltd., Joslin Diabetes Center, Lexicon Pharmaceuticals, DexCom, Inc., University of Washington, Breakthrough T1D
Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure
12/28
05/29
NATRIURETIC, NCT04535960: Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "" Trial

Recruiting
2
36
Canada
Empagliflozin 25 MG + Liraglutide 1.8 MG, Generic names are above, listed, Liraglutide 1.8 MG + Empagliflozin 25 MG
University Health Network, Toronto
Type 2 Diabetes Mellitus
10/23
10/23
DAPA-SWEET, NCT04258371: DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk

Recruiting
2
50
Canada
Dapagliflozin 10 MG, Placebo oral tablet
University Health Network, Toronto, Sunnybrook Health Sciences Centre, MOUNT SINAI HOSPITAL
Cardiovascular Risk Factor
12/23
12/23
ASPIRE, NCT06072326: Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruiting
2
36
Europe, Canada, US
Sotagliflozin, Ambrisentan, Ambrisentan and Sotagliflozin
University Medical Center Groningen, Juvenile Diabetes Research Foundation, Lexicon Pharmaceuticals
Type 1 Diabetes Mellitus With Diabetic Nephropathy
03/25
03/25
TREASURE-CKD, NCT05536804 / 2021-005273-47: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Recruiting
2
140
Europe, Canada, US, RoW
Tirzepatide, Placebo
Eli Lilly and Company, Eli Lilly and Company
Overweight, Obesity, Chronic Kidney Disease, Type 2 Diabetes, T2D
01/26
02/26
RT1D, NCT05822609: Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes

Recruiting
2
60
Canada, US
Semaglutide, Placebo
University of Washington, Juvenile Diabetes Research Foundation, University of Colorado, Denver, Providence Healthcare, University of Toronto
Diabetic Kidney Disease, Type 1 Diabetes
06/26
06/26
Overgaard, Chris
No trials found
Tavares, Suzana
No trials found

Download Options